IP Library Granted Patent US 12,208,121
Granted Patent B2
US 12,208,121 · App. 18/176,797 · Granted Jan 28, 2025

Spray-dried human plasma

Inventors: Joseph DaCorta (Durham, NC); Keith Rosiello (Beverly, MA)
Assignee: Velico Medical, Inc.
A61K35/16A61K9/14A61K9/1682B01D1/18A61K9/16B01D1/20G01N33/49
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,121
App. No.
18/176,797
Granted
Jan 28, 2025
Kind
B2
Abstract

The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.

Claims (26)

1. A method for spray-drying plasma derived from blood, the method comprising:

providing plasma derived from blood to a spray-drying apparatus;

spray-drying the plasma with the spray-drying apparatus to form physiologically-active plasma powder, the spray-drying apparatus configured utilizing one or more parameters; wherein during spray drying, the spray-drying apparatus determines an outlet temperature; and adjusts a pump setting and/or an inlet temperature of the spray-drying apparatus based on the outlet temperature; and

storing the physiologically-active plasma powder.

2. The method of claim 1 , wherein the one or more parameters comprise an inlet temperature, a pump setting, an aspiration setting, a spray flow rate, an outlet temperature, or any combination thereof.

3. The method of claim 1 , wherein the one or more parameters comprise an inlet temperature of substantially 107° C., a pump setting of substantially 24%, an aspiration setting of substantially 100%, a spray flow rate of substantially 35 mm Hg, an outlet temperature of substantially between 40° to 44° C., or any combination thereof.

4. The method of claim 3 , wherein the spray flow rate is nitrogen flow rate.

5. The method of claim 1 , wherein the one or more parameters comprise an inlet temperature of substantially between 100° to 114° C., a pump setting of substantially between 18 to 28%, an aspiration setting of substantially between 80% to 100%, a spray flow rate of substantially between 30 to 40 mm Hg, an outlet temperature of substantially between 40° to 44° C., or any combination thereof.

6. The method of claim 1 , further comprising reconstituting the physiologically-active plasma powder utilizing a reconstitution fluid to form physiologically-active reconstituted plasma.

7. The method of claim 6 , further comprising transfusing the physiologically-active reconstituted plasma into a human.

8. The method of claim 6 , wherein a recovery rate of physiologically-active functional proteins in the reconstituted plasma ranges from 50% to 90%, as compared to physiologically functional plasma proteins in plasma prior to spray drying.

9. The method of claim 6 , wherein the reconstitution fluid comprises distilled water, glycine, or any combination thereof.

10. The method of claim 1 , wherein the plasma comprises human plasma.

11. The method of claim 1 , wherein the adjusting a pump setting and/or an inlet temperature based on the outlet temperature further comprises adjusting a pump setting and/or an inlet temperature if the outlet temperature is not between substantially 40° to 44° C.

12. The method of claim 1 , further comprising applying the physiologically-active plasma powder directly to a human via application of the physiologically-active plasma powder directly to a wound on the human.

13. A spray-dried physiologically-active plasma powder-prepared by made from the steps of:

providing plasma derived from blood to a spray-drying apparatus;

spray-drying the plasma with the spray-drying apparatus to form the physiologically-active plasma powder, the spray-drying apparatus configured utilizing one or more parameters, wherein during spray drying, the spray-drying apparatus determines an outlet temperature; and adjusts a pump setting and/or an inlet temperature of the spray-drying apparatus based on the outlet temperature.

14. The spray-dried physiologically-active plasma powder of claim 13 , wherein the one or more parameters comprise an inlet temperature, a pump setting, an aspiration setting, a spray flow rate, an outlet temperature, or any combination thereof.

15. The spray-dried physiologically-active plasma powder of claim 13 , wherein the one or more parameters comprise an inlet temperature of substantially 107° C., a pump setting of substantially 24%, an aspiration setting of substantially 100%, a spray flow rate of substantially 35 mm Hg, an outlet temperature of substantially between 40° to 44° C., or any combination thereof.

16. The spray-dried physiologically-active plasma powder of claim 15 , wherein the spray flow rate is nitrogen flow rate.

17. The spray-dried physiologically-active plasma powder of claim 13 , wherein the one or more parameters comprise an inlet temperature of substantially between 100° to 114° C., a pump setting of substantially between 18 to 28%, an aspiration setting of substantially between 80% to 100%, a spray flow rate of substantially between 30 to 40 mm Hg, an outlet temperature of substantially between 40° to 44° C., or any combination thereof.

18. A physiologically-active reconstituted plasma derived from blood made from the steps of prepared by:

providing plasma derived from blood to a spray-drying apparatus;

spray-drying the plasma with the spray-drying apparatus to form physiologically-active plasma powder, the spray-drying apparatus configured utilizing one or more parameters, wherein during spray drying, the spray-drying apparatus determines an outlet temperature; and adjusts a pump setting and/or an inlet temperature of the spray-drying apparatus based on the outlet temperature; and

reconstituting the physiologically-active plasma powder utilizing a reconstitution fluid to form the physiologically-active reconstituted plasma.

Assignments (5)
COURT ORDER Recorded Nov 23, 2025
From: ROSIELLO, KEITH; KROSS ENGINEERING, LLC
To: ENTEGRION, INC.
Reel/Frame 073078/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: ENTEGRION, INC
To: VELICO MEDICAL, INC
Reel/Frame 072707/0092 →
COURT ORDER Recorded Oct 28, 2025
From: ROSIELLO, KEITH; KROSS ENGINEERING LLC
To: ENTEGRION, INC.
Reel/Frame 073387/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2025
From: ROSIELLO, KEITH
To: KROSS ENGINEERING LLC
Reel/Frame 072023/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2025
From: DACORTA, JOSEPH A.
To: ENTEGRION, INC.
Reel/Frame 072023/0527 →